Details for Patent: RE44599
✉ Email this page to a colleague
Title: | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Abstract: | Compounds that inhibit P13K.delta. activity, including compounds that selectively inhibit P13K.delta. activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (P13K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which P13K.delta. plays a role in leukocyte function, using the compounds also are disclosed. |
Inventor(s): | Fowler; Kerry W. (Seattle, WA), Huang; Danwen (Sammamish, WA), Kesicki; Edward A. (Bothell, WA), Ooi; Hua Chee (Kirkland, WA), Oliver; Amy (Bothell, WA), Ruan; Fuqiang (Bellevue, WA), Treiberg; Jennifer (Redmond, WA), Puri; Kamal Deep (Lynnwood, WA) |
Assignee: | ICOS Corporation (Indianapolis, IN) |
Filing Date: | Dec 28, 2012 |
Application Number: | 13/730,276 |
Claims: | 1. A method of inhibiting a growth or a proliferation of cancer cells of hematopoietic origin comprising contacting the cancer cells with an effective amount of a compound, wherein said compound is ##STR00183## or a pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the cancer .[.of hematopoietic origin is.]. .Iadd.cells are .Iaddend.lymphoma, leukemia, or multiple myeloma .Iadd.cells.Iaddend.. 3. The method of claim 2, wherein the compound or the pharmaceutically acceptable salt thereof is the S-enantiomer. 4. A method of treating a condition in a subject, wherein the condition is lymphoma, leukemia or multiple myeloma, comprising administering to the subject an effective amount of a compound, wherein the compound is .[.5-fluoro-3-phenyl-2-[1-(9H-purin-6 -ylamino)-propyl]-3H-quinazolin-4-one.]. ##STR00184## or a pharmaceutically acceptable salt thereof. 5. The method of claim 4, wherein the condition is selected from the group consisting of Burkitt's lymphoma, Hodgkins' lymphoma, non-Hodgkins lymphoma, lymphocytic lymphoma, lymphocytic leukemia, multiple myeloma and chronic myeloid leukemia. 6. The method of claim 4, wherein the compound or the pharmaceutically acceptable salt thereof is the S-enantiomer. |